ArticleAmerican journal of ophthalmology2022
The Blue Light Hazard Versus Blue Light Hype.
Article in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- The effect of fingolimod (FTY720) protecting the retina of rats from light-induced retinal degeneration (LIRD).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- The role of blue light-filtering and premium intraocular lenses on postoperative falls: A nationwide target trial emulation in Taiwan.Biomedical journal · 2026Article
- Lens Color and Macular Pigment Density after Cataract Surgery: A Randomized Clinical Trial.Ophthalmology science · 2026Article
- Photooxidative molecular damage under blue light.Experimental & molecular medicine · 2026Review
- [Climate change as a factor in the development of retinal diseases: a critical review].Die Ophthalmologie · 2025Review
- Exploring patient preferences for intraocular lenses selection in age-related cataract: a discrete choice experiment study.Frontiers in medicine · 2025Article
- Understanding the Impact of Polyunsaturated Fatty Acids on Age-Related Macular Degeneration: A Review.International journal of molecular sciences · 2024Review
- Spectral Dependence of Light Exposure on Retinal Pigment Epithelium Disruption in Living Primate Retina.Investigative ophthalmology & visual science · 2024Article
- Recent Advances in Our Understanding of Age-Related Macular Degeneration: Mitochondrial Dysfunction, Redox Signaling, and the Complement System.Aging and disease · 2024Review
- Blue Light Filtration in Intraocular Lenses: Effects on Visual Function and Systemic Health.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Oxidative stress in the eye and its role in the pathophysiology of ocular diseases.Redox biology · 2023Review
- Article
- Blue Light Exposure: Ocular Hazards and Prevention-A Narrative Review.Ophthalmology and therapy · 2023Review
- Effect of Violet Light-Filtering and Manufacturing Improvements in an Extended Depth-of-Focus Intraocular Lens on Visual Performance.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Radiology blues: Comparing occupational blue-light exposure to recommended safety standards.SA journal of radiology · 2023Article
- Impact of the Aging Lens and Posterior Capsular Opacification on Quantitative Autofluorescence Imaging in Age-Related Macular Degeneration.Translational vision science & technology · 2022Article
- Can Nutrition Play a Role in Ameliorating Digital Eye Strain?Nutrients · 2022Review
- Blue-light-filtering spectacle lenses in managing vision-related symptoms: an updated review.Therapeutic advances in ophthalmologyReview
- The evidentiary basis and challenges associated with studying the role of light damage on ocular health.Journal of optometryReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
purposeThe blue light hazard is the experimental finding that blue light is highly toxic to the retina (photic retinopathy), in brief abnormally intense exposures, including sungazing or vitreoretinal endoillumination. This term has been misused commercially to suggest, falsely, that ambient environmental light exposure causes phototoxicity to the retina, leading to age-related macular degeneration (AMD). We analyze clinical, epidemiologic, and biophysical data regarding blue-filtering optical chromophores.
designPerspective.
methodsAnalysis and integration of data regarding the blue light hazard and blue-blocking filters in ophthalmology and related disciplines.
resultsLarge epidemiologic studies show that blue-blocking intraocular lenses (IOLs) do not decrease AMD risk or progression. Blue-filtering lenses cannot reduce disability glare because image and glare illumination are decreased in the same proportion. Blue light essential for optimal rod and retinal ganglion photoreception is decreased by progressive age-related crystalline lens yellowing, pupillary miosis, and rod and retinal ganglion photoreceptor degeneration. Healthful daily environmental blue light exposure decreases in older adults, especially women. Blue light is important in dim environments where inadequate illumination increases risk of falls and associated morbidities.
conclusionsThe blue light hazard is misused as a marketing stratagem to alarm people into using spectacles and IOLs that restrict blue light. Blue light loss is permanent for pseudophakes with blue-blocking IOLs. Blue light hazard misrepresentation flourishes despite absence of proof that environmental light exposure or cataract surgery causes AMD or that IOL chromophores provide clinical protection. Blue-filtering chromophores suppress blue light critical for good mental and physical health and for optimal scotopic and mesopic vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.